AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 121 min read$JNJ

Wengel Kathryn E sold $2.4M of JNJ

Wengel Kathryn E (EVP, Chief TO and Risk Officer) sold 10,000 shares of JOHNSON & JOHNSON (JNJ) at $241.15 ($2.41M total) on 2026-06-11.

Original reporting
SEC EDGAR · Wengel Kathryn E
Published Jun 12, 2026, 9:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 9:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$JNJ
Neutral
medium confidence
Mentioned
$JNJ
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JNJNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings of an EVP/CRO risk officer.

02

Market read

Provides incremental sentiment/flow information via insider selling, but lacks any accompanying fundamental catalyst.

03

What to watch

No 10b5-1 plan is indicated in the filing; traders may overinterpret this, but without additional context (e.g., multiple concurrent sales, size relative to holdings, or follow-on buys) it remains weak evidence.

Relevance 6/10Novelty 2/10Timing: Filed 2026-06-12; sale executed 2026-06-11.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Johnson & Johnson.

Company-level read

Ticker impact

$JNJNeutralMedium confidence
Context

Johnson & Johnson disclosed an EVP sale: Wengel Kathryn E sold 10,000 shares on 2026-06-11 at $241.15 via an open-market transaction.

Expected impact

Low likelihood of a sustained price move; any impact is likely limited to short-term sentiment/flow optics.

Evidence & confidence

This is a Form 4 open-market sale with no 10b5-1 plan stated; however, the filing is not accompanied by new company fundamentals, guidance, or regulatory/product developments.

Market effects

Sector

Minimal; single-insider transaction does not reset sector expectations for large-cap healthcare.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be driven by diversification, taxes, or pre-existing compensation/portfolio management rather than a view on JNJ fundamentals.

Key entities

  • issuer
    Johnson & Johnson

    Subject of the SEC Form 4 insider transaction disclosure.

  • insider
    Wengel Kathryn E

    EVP, Chief TO and Risk Officer who sold 10,000 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

JNJ insider trading history →

Related articles

SEP 25
$JNJHigh

The 1 Number That Decides Whether a Dividend Lasts Your Whole Retirement

Johnson & Johnson (JNJ) extended its 64-year dividend growth streak with a 3.1% quarterly raise, supported by projected $21 billion in free cash flow. The company's oncology drugs, like CARVYKTI and TREMFYA, offset losses from Stelara biosimilars. JNJ's dividend yield is 1.94%, and shares are up 31.11% year-to-date. The company aims for a 65th consecutive hike in 2027, subject to free cash flow and litigation risks.

aol.com2 min
SEP 25
$JNJHighAI 8/10

Johnson & Johnson Reports TREMFYA STAR Trial Results

Johnson & Johnson (JNJ) reported positive Phase 4 STAR trial results for TREMFYA in treating axial psoriatic arthritis. The drug met primary and major secondary endpoints, showing improvements in disease activity, axial symptoms, and MRI-measured inflammation at Week 24. The safety profile was consistent with previous findings. Detailed results will be presented at a future scientific congress.

grafa.com2 min
SEP 25
$JNJLow

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

Johnson & Johnson (JNJ) reported that 50% of patients in a Phase 2 study of CARVYKTI® (ciltacabtagene autoleucel) for early-line relapsed/refractory multiple myeloma achieved five-year treatment-free remission. The study, presented at the International Myeloma Society Annual Meeting, showed a 69.2% five-year overall survival rate and 60.5-month median progression-free survival. The company suggests earlier treatment may increase long-term remission and disease control.

prnewswire.com2 min
SEP 25
$JNJMedAI 8/10

Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study

Johnson & Johnson (JNJ) reported positive results from the Phase 4 STAR study of TREMFYA (guselkumab) in patients with axial psoriatic arthritis (PsA). The drug met primary and major secondary endpoints, showing improvement in spinal pain, stiffness, and MRI-confirmed inflammation. JNJ aims to position TREMFYA as a first-line treatment for axial PsA, an area with significant unmet needs. Detailed results will be presented at an upcoming scientific congress.

prnewswire.com2 min
SEP 25
$JNJMedAI 8/10

Half of patients in a J&J study were alive without worsening myeloma five years after one infusion

Johnson & Johnson (JNJ) reported that 50% of patients in a Phase 2 study of CARVYKTI® for multiple myeloma were alive and progression-free five years after a single infusion. The study, presented at the International Myeloma Society Annual Meeting, showed a 69.2% overall survival rate and 60.5-month median progression-free survival. CARVYKTI is approved in 17 markets and has treated over 13,000 patients globally, according to the company.

stocktitan.net2 min